tradingkey.logo
tradingkey.logo

Precipio Inc

PRPO
24.790USD
-1.750-6.59%
Close 03/30, 16:00ETQuotes delayed by 15 min
16.45KMarket Cap
LossP/E TTM

Precipio Inc

24.790
-1.750-6.59%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Precipio Inc

Currency: USD Updated: 2026-03-27

Key Insights

Precipio Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 150 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Precipio Inc's Score

Industry at a Glance

Industry Ranking
150 / 208
Overall Ranking
433 / 4542
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Precipio Inc Highlights

StrengthsRisks
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. The Company’s technologies include HemeScreen and IV-Cell. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. Its technology enables testing to be completed in one rapid scanning process. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its product category includes Molecular Kits and IV-Cell Cytogenetics Media. The Molecular Kits include Quantitative MPN Panel, ABL1 Resistance Panel, and others. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 96.90% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.53M.
Undervalued
The company’s latest PE is -32.24, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 342.90K shares, increasing 20.32% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 14.50K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.14.

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Precipio Inc is 4.51, ranking 207 out of 208 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 6.77M, representing a year-over-year increase of 29.91%, while its net profit experienced a year-over-year increase of 87.38%.

Score

Industry at a Glance

Previous score
4.51
Change
0

Financials

4.97

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

4.06

Operational Efficiency

4.51

Growth Potential

4.00

Shareholder Returns

5.00

Precipio Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Precipio Inc is 7.46, ranking 83 out of 208 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -32.24, which is -98.90% below the recent high of -0.36 and -13.02% above the recent low of -36.43.

Score

Industry at a Glance

Previous score
7.46
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 150/208
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

No earnings forecast score is currently available for Precipio Inc. The Healthcare Equipment & Supplies industry's average is 7.78.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Precipio Inc is 7.52, ranking 17 out of 208 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 29.30 and the support level at 22.88, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.06
Change
-1.54

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.881
Neutral
RSI(14)
41.150
Neutral
STOCH(KDJ)(9,3,3)
5.742
Oversold
ATR(14)
1.616
High Vlolatility
CCI(14)
-262.172
Oversold
Williams %R
100.000
Oversold
TRIX(12,20)
0.418
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
26.049
Sell
MA10
26.990
Sell
MA20
26.910
Sell
MA50
24.881
Sell
MA100
24.071
Buy
MA200
20.064
Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Precipio Inc is 3.00, ranking 135 out of 208 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 19.57%, representing a quarter-over-quarter increase of 59.29%. The largest institutional shareholder is The Vanguard, holding a total of 25.56K shares, representing 1.46% of shares outstanding, with 24.36% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
AMH Equity, Ltd.
150.00K
+14.42%
Eklund (David A)
84.25K
--
Cohen (David Seth)
53.69K
+1.41%
Topline Capital Management, LLC
65.10K
--
BlackRock Institutional Trust Company, N.A.
28.91K
--
The Vanguard Group, Inc.
Star Investors
20.19K
+14.41%
Sandberg (Richard A)
25.18K
+248.20%
Geode Capital Management, L.L.C.
15.60K
+2.50%
Andrews (Ronald Asbury)
15.80K
+3.73%
Cossman (Jeffrey M.D.)
15.34K
+4.05%
1
2

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Precipio Inc is 2.96, ranking 137 out of 208 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.18. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
2.96
Change
0
Beta vs S&P 500 index
1.16
VaR
+6.84%
240-Day Maximum Drawdown
+25.32%
240-Day Volatility
+99.92%

Return

Best Daily Return
60 days
+7.41%
120 days
+18.80%
5 years
+40.82%
Worst Daily Return
60 days
-10.34%
120 days
-10.34%
5 years
-29.37%
Sharpe Ratio
60 days
+1.07
120 days
+0.99
5 years
+0.09

Risk Assessment

Maximum Drawdown
240 days
+25.32%
3 years
+67.35%
5 years
+94.44%
Return-to-Drawdown Ratio
240 days
+14.17
3 years
+0.58
5 years
-0.14
Skewness
240 days
+1.97
3 years
+1.07
5 years
+0.98

Volatility

Realised Volatility
240 days
+99.92%
5 years
+95.20%
Standardised True Range
240 days
+4.98%
5 years
+5.12%
Downside Risk-Adjusted Return
120 days
+183.48%
240 days
+183.48%
Maximum Daily Upside Volatility
60 days
+50.60%
Maximum Daily Downside Volatility
60 days
+48.46%

Liquidity

Average Turnover Rate
60 days
+0.79%
120 days
+0.78%
5 years
--
Turnover Deviation
20 days
+13.79%
60 days
+35.05%
120 days
+32.74%

Peer Comparison

Healthcare Equipment & Supplies
Precipio Inc
Precipio Inc
PRPO
4.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc
TMO
8.39 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Bioventus Inc
Bioventus Inc
BVS
8.28 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Anika Therapeutics Inc
Anika Therapeutics Inc
ANIK
8.13 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Lantheus Holdings Inc
Lantheus Holdings Inc
LNTH
8.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.05 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI